Please wait while we load the requested 10-K report or click the link below:
|||Total Product Net Sales Increased 32 Percent for the Fourth Quarter|
|||Fourth Quarter Total Product Net Sales Exceed $1 Billion for the First Time|
|||Full Year Total Product Net Sales Reach $3.9 Billion, a 29 Percent Increase|
|||Board of Directors Declares Fourth Quarter Dividend|
|||Allergan reported $0.52 diluted earnings per share from continuing operations compared to $0.45 diluted earnings per share reported for the fourth quarter of 2006.|
|||Allergans adjusted diluted earnings per share from continuing operations were $0.60 in the fourth quarter of 2007, compared to adjusted diluted earnings per share of $0.51 in the fourth quarter of 2006, a 17.6% year-over-year increase.|
|||Allergans total product net sales were $1,075.1 million. Total product net sales increased 31.7 percent, or 27.3 percent at constant currency, compared to total product net sales in the fourth quarter of 2006.|
|°||Total specialty pharmaceuticals net sales increased 24.5 percent, or 20.3 percent at constant currency, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2006.|
|°||Total core medical devices net sales increased 70.1 percent, or 65.0 percent at constant currency, compared to total core medical devices net sales in the fourth quarter of 2006.|
The following information was filed by Allergan Inc on Wednesday, January 30, 2008 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Allergan Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Allergan Inc.